Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04675723 · ClinicalTrials.gov registry record
The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection
A clinical trial of Clostridioides Difficile Infection, sponsored by Mayo Clinic.
- Completed
- Registry status
- 52
- Enrollment target
- 1
- Study location
NCT04675723: Completed study of Clostridioides Difficile Infection, sponsored by Mayo Clinic.
NCT04675723 is a study of Clostridioides Difficile Infection that has completed, run by Mayo Clinic. The registered enrollment target is 52 participants, below the 417-participant average among 6 other Clostridioides Difficile Infection trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04675723, a study of Clostridioides Difficile Infection, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is being done to identify types of bacteria associated with the lining of the large intestine in people who have recently been treated for C. difficile infection to determine if there are features associated with recurrent disease.
Primary Outcome
Identification of C. difficile within the colonic mucosa on stained slides from biopsy samples
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-09-23 |
| Est. Completion | 2022-05-05 |
What the finished NCT04675723 record still lists
NCT04675723 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 417-participant average among 6 other Clostridioides Difficile Infection trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Clostridioides Difficile Infection appearing as the primary indexed condition, and to 0 interventions.
NCT04675723 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04675723 about?
NCT04675723 is a clinical study titled "The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection". The study is being done to identify types of bacteria associated with the lining of the large intestine in people who have recently been treated for C. difficile infection to determine if there are features associated with recurrent disease.
What is the current status of trial NCT04675723?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2019-09-23. Estimated completion is 2022-05-05.
What conditions does trial NCT04675723 study?
This clinical trial studies the following conditions: Clostridioides Difficile Infection.
Who is sponsoring clinical trial NCT04675723?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04675723 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clostridioides Difficile Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
LMN-201 for Prevention of C. Difficile Infection Recurrence
RECRUITING · Phase 2
-
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
RECRUITING · Phase 2
-
Evaluation of GeoHAI Implementation
RECRUITING · NA
-
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
RECRUITING · Phase 3
-
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
RECRUITING · Phase 2
-
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI